- Synthesis, characterization and crystal structure of N-(4-(4-Fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide
-
N-[4-(4-Fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl]-N-methylmethane sulfonamide (I), an important intermediate to synthesize rosuvastatin, an HMG-CoA reductase inhibitor. It was prepared from methyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylamino)pyrimidine-5-carboxylate (1) via mesylation by mesyl chloride and sodium tert-pentoxide, then reduction by DIBAL/HCl. The product was characterized by NMR and LC-MS. The crystal structure of compound I was investigated using X-ray diffraction and SHELXTL-97 software. The result indicated that compound I crystallized in the monoclinic system, space group C2/C with a = 29.683(6), b = 7.6290 (15), c = 18.215(4) ?, V = 3451.1 (16) ?3; Z 8.
- Xu, Jia-Ying,Cheng, Wei-Hua,Zhu, Xun,Wu, Huan-Ling,Wang, Kai
-
-
Read Online
- An efficient, cyanide free total synthesis of rosuvastatin calcium
-
A simple, efficient, cyanide-free protocol for the total synthesis of rosuvastatin calcium was developed from inexpensive, commercially available D-arabinose; the key steps employed were Wittig reaction followed by oxa-Michael addition. The developed synthetic protocol could be adopted for industrial production of rosuvastatin calcium.
- Vempala, Naresh,Matta, Balaji,Rao, S. Venkateswara,Maddirala, Shambabu Joseph,Shree, A. Jaya
-
-
- Method for preparing rosuvastatin calcium intermediate
-
The invention discloses a preparation method for synthesizing a rosuvastatin calcium intermediate. The method comprises the following steps: taking 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-methoxycarbonyl-2-(N-methyl-N-methane sulfonamide) pyrimidine ester shown as formula (II) as a raw material; adding a metal borohydride, in an inert organic solvent, adding BF3 at the temperature of -20 DEG Cto 20 DEG C; raising the temperature to 40-100 DEG C and reacting; treating an obtained reacted solution A, and dissolving obtained 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-methoxycarbonyl-2-(N-methyl-N-methanesulfonamido) pyrimidine-5-methanol shown as formula (III) in an organic solvent; adding a catalyst and a co-catalyst, reacting fully at 20 to 100 DEG C at the air or oxygen atmosphere to obtain a reaction solution B, and carrying out aftertreatment on the reaction solution B to obtain 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-methoxycarbonyl-2-(N-methyl-N-methane sulfonamide) pyrimidine-5-formaldehyde as shown in formula (IV). The method is mild in condition and simple in aftertreatment, the production cost is reduced, and the molar yield of the product is high.
- -
-
Paragraph 0025-0045
(2020/04/17)
-
- Resuvastatin calcium parent nuclei and synthesis method thereof
-
The invention discloses resuvastatin calcium nuclei and a synthesis method thereof and relates to the technical field of drug intermediate synthesis. The synthesis method includes following steps: 1),under protection effect of inert gas, taking 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidine-5-methyl formate as a starting raw material, and adding the same into an organic solvent; 2), adding sodium disulfide, dropwise adding an organic solvent solution of red aluminum, rising temperature to 35-45 DEG C, and allowing reaction for 3-5h to obtain an initial product;3), quenching, separating, drying, evaporating to remove the solvent, and recrystallizing to obtain the resuvastatin calcium nuclei. The synthesis method is short in reaction process, simple in process, mild in reaction condition and convenient for control, can directly realize layering of different phases in the process of quenching, does not generate a lot of solid aluminum salt, does not causethe problem that the resuvastatin calcium nuclei are difficult to treat caused by the fact that the solid aluminum salt adsorbs the resuvastatin calcium nuclei, does not generate big impurities and ishigh in product purity and yield.
- -
-
Paragraph 0041-0078
(2019/05/22)
-
- Method for synthesizing rosuvastatin calcium intermediate impurity
-
The invention discloses a method for synthesizing a rosuvastatin calcium intermediate impurity. The method comprises the following steps: preparing 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl) amino] pyrimidine-5-methanol (3) from 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl) amino] pyrimidine-5-methyl carboxylate (2) through reduction; preparing 5-(bromine methyl)-4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidine (4) from the compound (3) through bromination; coupling the compound (4) with the 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl) amino] pyrimidine-5-methanol (3) to generate N,N'-(5,5'-(oxo-di(methylene)) bi(4-(4-fluorophenyl)-6-isopropyl pyrimidine-5,2-di-yl)) bi(N-methyl methanesulfonamide) (1), so as toobtain the rosuvastatin calcium intermediate impurity with high impurity. The synthesized rosuvastatin calcium intermediate impurity can be used as an impurity standard substance in rosuvastatin calcium raw material detection and analysis, and accurate positioning and qualification of impurities in rosuvastatin calcium raw material detection and analysis can be improved; the method disclosed by the invention is cheap and easy in raw material obtaining and simple in operation, the product yield is 65+/-5%, and the HPLC (High Performance Liquid Chromatography) purity is greater than or equal to99%.
- -
-
Paragraph 0014-0018
(2018/07/30)
-
- A method for preparing a rosuvastatin calcium intermediate
-
The invention relates to the technical field of pharmaceutical chemistry, particularly the field of process optimization and cost control for pharmaceutical intermediate preparation, and more particularly relates to an impurity in preparation of a rosuvastatin calcium intermediate and a method for synthesizing the intermediate from the impurity. A compound I' is reacted with ozone and a reductantto obtain a compound IV and an important intermediate III, the compound IV is further subjected to reduction and substitution to prepare another intermediate II important in preparation of the rosuvastatin calcium intermediate, and the compound II and the compound III are adopted to prepare an intermediate compound I. Through recovery and utilization of the impurity compound I', the preparation cost of the compound I is significantly reduced. The method is simple in process and suitable for industrial large-scale production.
- -
-
Paragraph 0024
(2019/01/08)
-
- Palladium-Catalyzed Stereoselective Cyclization of in Situ Formed Allenyl Hemiacetals: Synthesis of Rosuvastatin and Pitavastatin
-
A diastereoselective palladium-catalyzed cyclization of allenyl hemiacetals is described. It permits the selective synthesis of 1,3-dioxane derivatives, precursors for syn-configured 1,3-diols which make an appearance in all of the statin representatives. The reaction allows the total synthesis of Rosuvastatin and Pitavastatin in a straightforward fashion.
- Spreider, Pierre A.,Breit, Bernhard
-
supporting information
p. 3286 - 3290
(2018/06/11)
-
- Efficient Construction of the Nucleus of Rosuvastatin Calcium
-
A novel and efficient five-step synthetic route, including a Biginelli reaction, dehydrogenation, chlorination, sulfonamidation, and reduction, for the core of Rosuvastatin was established. All steps were systematically studied. Tert-butylhydroperoxide aqueous solution was applied in the dehydrogenation instead of nitric acid. N,N-dimethylaniline was employed as a catalyst to accelerate the chlorination proceeding smoothly, and its catalytic mechanism is discussed. In the sulfonamidation, the conversion of compound 5 was obviously improved by use of NaH and acetonitrile. In addition, two sulfonamidation side products 6 and 7 were detected and isolated. Thus, under the optimized reaction conditions, the target product was obtained in 60.4% total yield, much higher than the reported yield (36.4%).
- Zhou, Yingtao,Lin, Chenhui,Xing, Yuzhi,Chen, Ligong,Yan, Xilong
-
p. 1898 - 1903
(2017/05/29)
-
- Preparation method of rosuvastatin calcium intermediate
-
The invention provides a preparation method of a rosuvastatin calcium intermediate. The preparation method of the rosuvastatin calcium intermediate, namely, the compound shown as formula I in the description comprises the following steps: (1) a compound 5 shown as formula II in the description is generated from 4-fluorobenzaldehyde, methyl isobutyrylacetate and urea under the action of a catalyst; (2) a compound 6 shown as formula III in the description is generated from the compound 5 under the action of potassium persulfate as an oxidizing agent; (3) a compound 7 shown as formula IV in the description is generated from the compound 6, tosyl chloride and N-methyl methanesulfonamide under the action of a catalyst; (4) the target compound shown as the formula I is generated from the compound 7 under the action of a vitride solution as a reducing agent and crystallized with a crystallization solution, and a purified target compound is obtained. The preparation method of the rosuvastatin calcium intermediate has the advantages of low production cost, mild condition and simple and convenient operation.
- -
-
-
- METHOD FOR PREPARING ROSUVASTATIN SODIUM
-
The present invention belongs to the technical field of organic chemistry, and specifically relates to a method for preparing rosuvastatin sodium. The method of the invention comprises: reducing 4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)pyrimidine-5-carboxylic acid (VII) in the presence of a borohydride, an alkyl-substituted chlorosilane and an assistance in an organic solvent to prepare 4-p-fluorophenyl-5-hydroxymethyl-6-isopropyl-2-(N-methyl-methylsulfonylamino) pyrimidine (VIII); then performing a reaction of the compound VIII with a triphenyl phosphonium salt in an organic solvent to prepare a ((4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)-5-pyridyl)-methyl)triphenyl phosphonium salt (IX); performing a stereoselective Michael addition reaction of (S)-trans-4,5-dihydroxy-pent-2-olefine acid ester (II) with furfural (III) to prepare a 2-((4R,6S)-2-(furan-2-yl)-6-hydroxymethyl-1,3-dioxane-4-yl)acetate (IV); oxidizing the compound IV to prepare a 2-((4R,6S)-2-(furan-2-yl)-6-formacyl-1,3-dioxane-4-yl)acetate (V); performing an olefination reaction of the compound V with the (4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)pyrimid-5-yl)-methyl triphenyl substituted phosphonium salt (IX) or phosphate to prepare 2-((4R,6S)-6-(trans-2-(4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)pyrimid-5-yl)vinyl)-2-(furan-2-yl)-1,3-dioxane-4-yl)acetate (VI); and performing deprotection and sodium salt formation of compound VI to prepare rosuvastatin sodium (I). The method has easily obtainable raw materials, and is simple to operate and suitable for industrial productions.
- -
-
Paragraph 0041; 0042
(2017/07/14)
-
- Stereocontrolled synthesis of rosuvastatin calcium via iodine chloride-induced intramolecular cyclization
-
A novel, stereoselective approach towards rosuvastatin calcium from the known (S)-homoallylic alcohol has been developed. The synthesis is highlighted by a regio- and stereocontrolled ICl-induced intramolecular cyclization of chiral homoallylic carbonate to deliver the C6-formyl statin side chain with a syn-1,3-diol moiety. An improved synthesis of the rosuvastatin pyrimidine core moiety is also included. Moreover, this methodology is useful in the asymmetric synthesis of structural variants of statins such as pitavastatin calcium and atorvastatin calcium and their related analogs.
- Xiong, Fangjun,Wang, Haifeng,Yan, Lingjie,Han, Sheng,Tao, Yuan,Wu, Yan,Chen, Fener
-
p. 1363 - 1369
(2016/02/03)
-
- Metal-free, visible-light photoredox catalysis: Transformation of arylmethyl bromides to alcohols and aldehydes
-
A mild, simple, and controllable metal-free photocatalytic system for the transformation of arylmethyl bromides to corresponding alcohols and aldehydes in high yields with visible-light irradiation has been achieved. Eosin Y was found to be an efficient promoter for this oxidative dehalogenation reaction under photo irradiation conditions.
- Li, Jian,Wang, Hongni,Liu, Li,Sun, Jiangtao
-
p. 49974 - 49978
(2014/12/10)
-
- METHOD FOR PREPARING ROSUVASTATIN CALCIUM INTERMEDIATE
-
Disclosed is a method for preparing rosuvastatin calcium intermediate of formula I, which comprises hydrolyzing an ester compound of formula II (R is C1-C5 alkyl) in the presence of a metal compound to obtain a carboxylic acid compound of formula III, and then reducing the carboxylic acid compound under a specific reduction condition to obtain rosuvastatin calcium intermediate of formula I.
- -
-
-
- METHOD FOR PREPARING ROSUVASTATIN CALCIUM INTERMEDIATE
-
A method for preparing a rosuvastatin calcium intermediate represented by formula I. The method includes: hydrolyzing an ester compound represented by formula II (in which, R represents C1-C5) in the presence of a metal compound to obtain a carboxylic acid compound represented by formula III; and reducing the carboxylic acid compound in the presence of a reductant.
- -
-
-
- PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF
-
The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvasatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2-N-O-R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.
- -
-
Page/Page column 18
(2012/01/14)
-
- Concise and highly efficient approach to three key pyrimidine precursors for rosuvastatin synthesis
-
We report the synthesis of 5-formyl-, 5-(hydroxymethyl)-, and 5-(bromomethyl) substituted N-[4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-N- methylmethanesulfonamide. The presented synthetic approach is based on highly efficient three step preparation of functionalized 5-methylpyrimidine. The methyl group is selectively brominated by NBS with irradiation into the bromomethyl derivative, which is then transformed into the hydroxymethyl or formyl groups in nearly quantitative yields. This approach is superior to the existing methodologies for the preparation of the key pyrimidine precursors used in the synthesis of rosuvastatin since no metal catalysis and no cryogenic reaction conditions are involved.
- ?terk, Damjan,?asar, Zdenko,Juki?, Marko,Ko?mrlj, Janez
-
p. 2155 - 2160
(2012/03/27)
-
- PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.
- -
-
-
- Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
-
The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.
- -
-
-
- KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The present invention relates in general to the field of organic chemistry and in particular to the preparation of N-(4-(4-fluorophenyl)-6-isopropyl-5-methylpyrimidin-2-yl)-N-methylmethanesulfonamide (I), N-(4-(4-fluorophenyl)-5-(bromomethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (II) and N-(4-(4-fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (III), key intermediates in preparation of Rosuvastatin.
- -
-
Page/Page column 11; 14
(2012/02/03)
-
- KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The present invention relates in general to the field of organic chemistry and in particular to the preparation of N-(4-(4-fluorophenyl)-6-isopropyl-5-methylpyrimidin-2-yl)-N- methylmethanesulfonamide (I), N-(4-(4-fluorophenyl)-5-(bromomethyl)-6-isopropylpyrimidin-2- yl)-N-methylmethanesulfonamide (II) and N-(4-(4-fluorophenyl)-5-(hydroxymethyl)-6- isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (III), key intermediates in preparation of Rosuvastatin.
- -
-
Page/Page column 25-26
(2010/08/09)
-
- A PROCESS FOR PREPARATION OF ROSUVASTATIN INTERMEDIATE
-
The present invention provides an improved process for the preparation of intermediates involved in the preparation of rosuvastatin. Particularly, the proposed invention is able to overcome the disadvantages associated with the known methods. Thus, the instant invention provides a process which is clean, economic, industrially scalable and provides high yields with substantially pure product.
- -
-
Page/Page column 15
(2010/04/06)
-
- A PROCESS FOR THE PREPARATION OF INTERMEDIATES OF ROSUVASTATIN
-
The present invention provides a process for the preparation of the rosuvastatin intermediates and their conversion to rosuvastatin or its pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 8; 16-17; 21-22
(2008/12/05)
-
- PREPARATION OF ALKYL 4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONY)AMINO]-PYRIMIDINE-5-CARBOXYLATE AND ITS SUBSEQUENT CONVERSION TO N-[4-(4-FLUOROPHENYL)-5-FORMYL-6-ISOPROPYL PYRIMIDIN-2-YL]-N-METHYLMETHANESULFONAMIDE-A KEY INTERMEDIATE IN THE SYNTHESIS OF ROSUVASTATIN
-
The present invention discloses a novel process to prepare a compound of formula (IIA). By reacting a compound of formula-[D], wherein R1 is C1 to C6 alkyl, preferably R1 is methyl or ethyl, more preferably R1 is methyl ; and R2 is C1 to C8 n-alkyl or branched alkyl, cycloalkyl, phenyl , benzyl or substituted phenyl group, preferably R2 is methyl ; with N-methyl methanesulfonamide and a base, optionally with a salt of N-methyl methanesulfonamide, in suitable solvent(s) , to give a compound of formula (IIA), followed by converting compound of formula (IIA) to a compound for formula -[B], by a known process and finally converting a compound of formula (B) to a compound of formula (II), by a novel process using calcium hypochlorite / TEMPO as an oxidant.
- -
-
Page/Page column 16
(2008/06/13)
-
- PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES
-
There is described a process for the preparation of compounds of formula (1) starting from the reaction of the compounds of formulae (24), (25) and (26) to form the compound of formula (23), wherein in each case R1, R2 and R3 are each independently of the others an unsubstituted or substituted organic radical; R4 is hydrogen, unsubstituted or substituted C1-C8alkyl, C1-C8alkoxy, phenoxy or benzyloxy, or halogen; Y1 and Y2 are each independently of the other hydrogen or a protecting group, or Y1 and Y2 together are a protecting bridge; and X1 is hydrogen, an organic radical or a cation; and also novel intermediates.
- -
-
-
- PROCESS FOR THE PREPARATION OF ROSUVASTATIN
-
The present invention relates to a cost effective and industrially advantageous process for the preparation of 4-4(fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)-5-pyrimidinecarboxaldehyde, referred to here as pyrimidine aldehyde of structural Formula I and to the use of this compound as intermediate for the preparation of rosuvastatin.
- -
-
Page/Page column 4; 11-12
(2008/06/13)
-
- Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors
-
A novel series of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates were synthesized and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Monocalcium bis(+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methanesulfonylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy- (E)-6-heptenoate (3a, S-4522) was selected as a candidate for further evaluation. Compound 3a was approximately four times more potent than lovastatin sodium salt (in inhibiting HMG-CoA reductase in vitro (IC50 = 11 nM). Compound 3a was shown to be the most potent cholesterol biosynthesis inhibitor in this series (IC50 = 1.12 nM) in rat isolated hepatocytes; its inhibitory activity was approximately 100 times more potent than pravastatin.
- Watanabe, Masamichi,Koike, Haruo,Ishiba, Teruyuki,Okada, Tetsuo,Seo, Shujiro,Hirai, Kentaro
-
p. 437 - 444
(2007/10/03)
-